The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Lilly; Merck; Novartis; Pfizer
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Expert Testimony - Bayer
 
Shukui Qin
No Relationships to Disclose
 
Masafumi Ikeda
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Gilead Sciences; Kaken Pharmaceutical; Lilly Japan; MSD; Mylan; Novartis; Otsuka; SERVIER; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly Japan; Micron; Novartis; Ono Pharmaceutical; SERVIER; Shire; Takeda; Teijin Pharma
Research Funding - ASLAN Pharmaceuticals (Inst); AstraZeneca (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst)
 
Peter R. Galle
Honoraria - Adaptimmune; Bayer Schering Pharma; Bristol-Myers Squibb; Ipsen; Lilly; MSD; Roche/Genentech; Sirtex Medical
Consulting or Advisory Role - Adaptimmune; Bayer Schering Pharma; Bristol-Myers Squibb; Lilly; MSD; Roche/Genentech; Sirtex Medical
Speakers' Bureau - Bayer Schering Pharma; Ipsen; Lilly; Roche
Travel, Accommodations, Expenses - Bayer Schering Pharma; Lilly; Sirtex Medical
 
Michel Ducreux
Employment - Sandoz (I)
Honoraria - Amgen; Bayer; Celgene; Ipsen; Lilly; Merck Serono; MSD Oncology; Novartis; Roche/Genentech; Servier
Consulting or Advisory Role - Amgen; Celgene; HalioDx; Ipsen; Lilly; Merck Serono; Novartis; Pierre Fabre; Roche; Servier
Speakers' Bureau - Bayer; Celgene; Ipsen; Merck KGaA; Roche
Research Funding - Keocyt (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Ipsen; Merck Serono; Roche
 
Tae-You Kim
No Relationships to Disclose
 
Ho Yeong Lim
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Eisai; MSD Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai
Speakers' Bureau - Bayer
 
Masatoshi Kudo
Honoraria - Bayer; Bristol-Myers Squibb Japan; EA Pharma; Eisai; Lilly Japan; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; MSD; Ono Pharmaceutical; Roche
Research Funding - Abbvie (Inst); EA Pharma (Inst); Eisai (Inst); Gilead Sciences (Inst); Otsuka (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Valeriy Vladimirovich Breder
Honoraria - Bayer; BioCad; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - Bayer; BioCad; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Ipsen; Roche; Takeda
 
Philippe Merle
Honoraria - AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Lilly; Merck; Roche
Consulting or Advisory Role - Bayer Schering Pharma
 
Ahmed Omar Kaseb
Honoraria - Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Consulting or Advisory Role - Bayer Health; Bristol-Myers Squibb; Eisai; Exelixis; Genentech/Roche; Merck
Research Funding - Adaptimmune (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Hengrui Pharmaceutical (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bayer/Onyx; Bristol-Myers Squibb; Exelixis; Merck
 
Daneng Li
Consulting or Advisory Role - Advanced Accelerator Applications; Eisai; Exelixis; Genentech; Ipsen; Lexicon; Taiho Pharmaceutical
Speakers' Bureau - Advanced Accelerator Applications; Coherus Biosciences; Eisai; Exelixis; Ipsen; Lexicon; Sun Pharma
Research Funding - Brooklyn ImmunoTherapeutics (Inst)
 
Wendy Verret
Employment - Roche/Genentech
 
Hui Shao
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Juan Liu
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Lindong Li
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis; Gilead Sciences; Gilead Sciences; Lilly; Merck; Roche/Genentech; Sanofi/Aventis
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst)
 
Ann-Lii Cheng
Honoraria - AstraZeneca; Bayer Health; BeiGene; Bristol-Myers Squibb; CSR Pharma; Eisai; Exelixis; F. Hoffmann LaRoche; Ipsen; IQVIA; Merck Serono; Merck Sharp & Dohme; Novartis; Nucleix; Ono Pharmaceutical; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bayer Health; BeiGene; Bristol-Myers Squibb; CSR Pharma; Eisai; Exelixis; F. Hoffmann LaRoche; Ipsen; IQVIA; Merck Serono; Merck Sharp & Dohme; Novartis; Nucleix; Ono Pharmaceutical; Roche/Genentech
Speakers' Bureau - Amgen; Bayer Yakuhin; Eisai; Novartis; Ono Pharmaceutical
Travel, Accommodations, Expenses - Bayer Yakuhin; IQVIA; Roche/Genentech